Typical variability dynamics of injected insulin Glargine (Lantus).

1. Figure 1: Patient inhaling Afrezza. The other two photos are of the device (open) and with the cartridge.

2. Figure 2: Kinetics of the Phase 1 and Phase 2 insulin releases from the pancreas of a healthy person (in response to a glucose spike) and the sum of the two curves.

3. Figure 3: Comparison of the pharmacokinetics of Afrezza to that of Rapid Acting Analog Insulin and to the pancreatic response to a spike of glucose.

4. Figure 4: Pharmacodynamics of Afrezza, Rapid Acting Analog Insulin and Regular Human Insulin as commercially sold.

5. Figure 5: Graphic illustrating how the late postprandial persistence of RAA Insulin causes hyperinsulinemia and a substantial drop in glucose, which offsets the high prandial peak that can lead to an average glucose below baseline and a misleading HbA1c. Also shown is the above baseline average glucose of an insulin such as Afrezza without the late persistence.

6. Typical variability dynamics of injected insulin Glargine (Lantus).